Eli Lilly has secured a transformative $2.75 billion deal with Insilico Medicine to enhance its drug development capabilities through artificial intelligence, with an upfront payment of $115 million. This strategic partnership is expected to accelerate the discovery of new therapeutics, bolstering Eli Lilly's pipeline amid fierce competition in the pharmaceutical sector. As demand for innovative treatments grows, the collaboration highlights Eli Lilly's commitment to advancing healthcare while addressing ongoing pressures in the market.
“Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market”
“Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market”
“Eli Lilly is trading at 26.6x forward earnings, compared to Novo Nordisk's forward price-to-earnings of 10.9, and the healthcare sector's average of 16.9. Perhaps at current levels, Eli Lilly's shares are just too expensive, while Novo Nordisk's are a bargain.”
“Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech”
“Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market.”
“What does Novo's oral Wegovy launch portend for Eli Lilly's hotly-anticipated pill? @BMO's Evan David Seigerman gives his read fresh from the firm's Metabolic Health Summit.”
“Eli Lilly e Insilico fecham acordo de até US$ 2,75 bi para medicamentos com IA”
“US drugmaker Eli Lilly will sign a $2bn deal with a Hong Kong-listed company that uses AI for drug discovery, according to sources familiar with the matter, highlighting the global pharmaceutical sector’s increasing reliance on medicines developed in China.”
“Eli Lilly firma acuerdo de US$ 2.750 millones con compañía hongkonesa para el desarrollo de fármacos con IA.”
“Novo Nordisk is cutting South African prices of its weight-loss drug Wegovy for a second time since it launched in August, local executives said on Wednesday, pointing to fierce competition in a market led by rival Eli Lilly.”
“How Eli Lilly’s cancer chief, Jacob Van Naarden, rewrote the company’s plans in oncology — and quietly became its top dealmaker. Also: why biotechs keep turning down good offers…”
“Hong Kong-listed AI drug discovery company Insilico Medicine and Eli Lilly sign a drug co-development deal worth up to $2.75B, with $115M in upfront payments.”
